Business News • PR NewsWire • Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis

Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis

Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis

SHR0302 monotherapy achieved positive results on reaching primary endpoints with statistical significance, delivering significant improvements in skin clearance Both doses were shown to be superior to placebo for key secondary endpoints AEs were manageable and generally transient and...

View More : https://www.prnewswire.com:443/news-releases/reistone-biopharma-announces-positive-topline-results-from-phase-2-clinical...

Releted News by prnewswire

Twenty-Seven Ohio Counties Added to Ambetter from Buckeye Health Plan Insurance Coverage

Llega el tráiler oficial para el nuevo documental sobre la marca Johnnie Walker del director Anthony Wonke, ganador de varios premios BAFTA

Academy Sports + Outdoors Announces Offering of Senior Secured Notes

Reistone Biopharma Announces Positive Topline Results from Phase 2 Clinical Trial Evaluating SHR0302, a JAK1 Inhibitor for the Treatment of Moderate-to-Severe Atopic Dermatitis

New Landmark Study at UM School of Medicine Finds Aspirin Use Reduces Risk of Death in Hospitalized COVID-19 Patients

Create Artistic Images with AKVIS ArtSuite 18.0: Now with Text!